Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
137 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2014', provides an overview of the Peripheral T-Cell Lymphomas (PTCL)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Peripheral T-Cell Lymphomas (PTCL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral T-Cell Lymphomas (PTCL) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Peripheral T-Cell Lymphomas (PTCL) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peripheral T-Cell Lymphomas (PTCL) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peripheral T-Cell Lymphomas (PTCL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Peripheral T-Cell Lymphomas (PTCL) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Peripheral T-Cell Lymphomas (PTCL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Peripheral T-Cell Lymphomas (PTCL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Peripheral T-Cell Lymphomas (PTCL) Overview 8 Therapeutics Development 9 Pipeline Products for Peripheral T-Cell Lymphomas (PTCL) - Overview 9 Pipeline Products for Peripheral T-Cell Lymphomas (PTCL) - Comparative Analysis 10 Peripheral T-Cell Lymphomas (PTCL) - Therapeutics under Development by Companies 11 Peripheral T-Cell Lymphomas (PTCL) - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Peripheral T-Cell Lymphomas (PTCL) - Products under Development by Companies 16 Peripheral T-Cell Lymphomas (PTCL) - Companies Involved in Therapeutics Development 17 Kyowa Hakko Kirin Co., Ltd. 17 Sanofi 18 ZIOPHARM Oncology, Inc. 19 Millennium Pharmaceuticals, Inc. 20 Novartis AG 21 Eisai Co., Ltd. 22 Celgene Corporation 23 Bayer AG 24 Incyte Corporation 25 Topotarget A/S 26 Mundipharma International Limited 27 Spectrum Pharmaceuticals, Inc. 28 Chipscreen Biosciences Ltd 29 AB Science 30 Rhizen Pharmaceuticals SA 31 Peripheral T-Cell Lymphomas (PTCL) - Therapeutics Assessment 32 Assessment by Monotherapy Products 32 Assessment by Target 33 Assessment by Mechanism of Action 36 Assessment by Route of Administration 39 Assessment by Molecule Type 41 Drug Profiles 43 alisertib - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 pralatrexate - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 HBI-8000 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 mogamulizumab - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 ruxolitinib phosphate - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 darinaparsin - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 masitinib - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 luminespib - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 romidepsin - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 alemtuzumab - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 forodesine hydrochloride - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 pralatrexate - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 belinostat - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 copanlisib - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 denileukin diftitox - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 TGR-1202 - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 SH-7129 - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Peripheral T-Cell Lymphomas (PTCL) - Recent Pipeline Updates 87 Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects 127 Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products 128 Peripheral T-Cell Lymphomas (PTCL) - Product Development Milestones 129 Featured News & Press Releases 129 Jul 07, 2014: FDA Grants Spectrum Pharmaceuticals Accelerated Approval of Beleodaq (belinostat) for Injection 129 Jul 03, 2014: BioAlliance Pharma Receives FDA approval for Beleodaq 130 Mar 17, 2014: Approval for Additional Indication for PTCL and CTCL of Mogamulizumab 131 Feb 06, 2014: FDA Grants Acceptance To File And Priority Review For TopoTarget A/S's Beleodaq NDA In PTCL 131 Dec 10, 2013: Spectrum Pharmaceuticals Announces Submission of New Drug Application for Belinostat, a novel pan-HDAC inhibitor 133 Dec 06, 2013: Spectrum Pharmaceuticals Highlights Abstracts On Folotyn at the 55th Annual Meeting of the American Society of Hematology 133 Dec 06, 2013: Spectrum Pharmaceuticals Highlights Abstracts On Marqibo at the 55th Annual Meeting of the American Society of Hematology 133 Aug 28, 2013: First patient dosed in part one confirmatory BelCHOP study in PTCL 134 Aug 08, 2013: Spectrum Pharmaceuticals announces postponement in filing of NDA for belinostat in PTCL to Q4 2013 134 Jul 19, 2013: Application Seeking Approval for Additional Indication for ATL, PTCL and CTCL of Mogamulizumab 135 Appendix 136 Methodology 136 Coverage 136 Secondary Research 136 Primary Research 136 Expert Panel Validation 136 Contact Us 137 Disclaimer 137
List of Tables Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H2 2014 9 Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL) - Comparative Analysis, H2 2014 10 Number of Products under Development by Companies, H2 2014 12 Comparative Analysis by Late Stage Development, H2 2014 13 Comparative Analysis by Clinical Stage Development, H2 2014 14 Comparative Analysis by Early Stage Development, H2 2014 15 Products under Development by Companies, H2 2014 16 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014 17 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Sanofi, H2 2014 18 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by ZIOPHARM Oncology, Inc., H2 2014 19 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 20 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Novartis AG, H2 2014 21 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Eisai Co., Ltd., H2 2014 22 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Celgene Corporation, H2 2014 23 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Bayer AG, H2 2014 24 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Incyte Corporation, H2 2014 25 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Topotarget A/S, H2 2014 26 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Mundipharma International Limited, H2 2014 27 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2014 28 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Chipscreen Biosciences Ltd, H2 2014 29 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by AB Science, H2 2014 30 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Rhizen Pharmaceuticals SA, H2 2014 31 Assessment by Monotherapy Products, H2 2014 32 Number of Products by Stage and Target, H2 2014 35 Number of Products by Stage and Mechanism of Action, H2 2014 38 Number of Products by Stage and Route of Administration, H2 2014 40 Number of Products by Stage and Molecule Type, H2 2014 42 Peripheral T-Cell Lymphomas (PTCL) Therapeutics - Recent Pipeline Updates, H2 2014 87 Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects, H2 2014 127 Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products, H2 2014 128
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
